
Sign up to save your podcasts
Or


In this week's View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol's effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension.
Subscribe to Eagle's Eye View
By American College of Cardiology4.7
129129 ratings
In this week's View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol's effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension.
Subscribe to Eagle's Eye View

136 Listeners

318 Listeners

498 Listeners

169 Listeners

884 Listeners

296 Listeners

1,149 Listeners

58 Listeners

39 Listeners

193 Listeners

94 Listeners

367 Listeners

428 Listeners

370 Listeners

35 Listeners